The current finding that systemic administration of a BBB permeable GCPII inhibitor can improve working memory performance in rats, with no evidence of side effects, encourages the further development of this mechanism for treating cognitive disorders in humans. The gene discussed is FOLH1; the disease is Cognitive impairment.